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Severe lung inflammation and alveolar hemorrhage can be life-threatening in systemic
lupus erythematosus (SLE) patients if not treated early and aggressively. Neutrophil influx is
the driver key of this pathology, but little is known regarding the molecular events regulating
this recruitment. Here, we uncover a role for IL-16/mir-125a in this pathology and show not
only that IL-16 is a target for miR-125a but that reduced miR-125a expression in SLE
patients associates with lung involvement. Furthermore, in the pristane model of acute
“SLE-like” lung inflammation and alveolar hemorrhage, we observed reduced pulmonary
miR-125a and enhanced IL-16 expression. Neutrophil infiltration was markedly reduced in
the peritoneal lavage of pristane-treated IL-16–deficient mice and elevated following i.n.
delivery of IL-16. Moreover, a miR-125a mimic reduced pristane-induced IL-16 expression
and neutrophil recruitment and rescued lung pathology. Mechanistically, IL-16 acts directly
on the pulmonary epithelium and markedly enhances neutrophil chemoattractant
expression both in vitro and in vivo, while the miR-125a mimic can prevent this. Our results
reveal a role for miR-125a/IL-16 in regulating lung inflammation and suggest this axis may
be a therapeutic target for management of acute lung injury in SLE.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical presentations that 
can affect multiple organs (1). Acute alveolar hemorrhage is a rare and potentially devastating form of  
acute respiratory distress syndrome (2, 3), with a mortality rate of  50%–70%. As with many other forms 
of  acute respiratory inflammation, including acute lung injury (4, 5), alveolar hemorrhage in SLE is asso-
ciated with a massive influx of  neutrophils into the airways (6, 7). Recently, neutrophils have been shown 
to be highly pathogenic in lupus cardiovascular and kidney disease, releasing inflammatory cytokines 
and immunostimulatory DNA in the form of  neutrophil extracellular traps (NETs) (8–10). This subset 
of  inflammatory, low-density neutrophils readily release NETs enriched in oxidized mitochondrial DNA, 
which further drives inflammation and type I IFN production. What drives inflammation and recruitment 
of  neutrophils to the lung in SLE is currently not known.
Type I IFNs and particularly IFN-α have emerged as key pathogenic cytokines in SLE (11, 12). 
Elevated IFN-α is observed in over 50% of  patients and correlates with disease severity, flare, and tissue 
involvement. In recent years, a type I IFN gene signature has been described in the peripheral blood 
of  SLE patients that correlates with increased disease activity (13–15). In addition, genetic association 
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studies have identified a number of  genes that are linked to IFN production or signaling, such as IRF5, 
TYK2, IFIH1, and TLR7 (16, 17). Type I IFNs have also recently been found to be central to inflam-
matory responses in the lung in response to viral or environmental challenges. Type I IFNs can induce 
the expression of  multiple chemokines, such as CCL2/MCP-1, CCL3/MIP-1α, CXCL1, CXCL2, and 
CXCL10/IP-10, influencing inflammation via recruitment and activation of  multiple cell types, includ-
ing neutrophils, monocytes, and T cells in the lung (18–27). While initially thought of  largely as a T cell 
chemoattractant, CXCL10 has been shown to play an important role in lung inflammation via regulating 
neutrophil recruitment (28).
Supporting a role for type I IFNs regulating lung inflammation in SLE, pristane-inducible murine 
lupus results in severe lung inflammation and pulmonary hemorrhaging in 70%–80% of  mice when 
pristane is administered on a C57BL/6 (B6) background (29, 30). TLR7-dependent production of  type 
I IFN production drives the pathology of  this model, with inflammatory type I IFN-producing mono-
cytes detectable in the peritoneal cavity as early as 3 days after pristane injection. Importantly, this pris-
tane-induced hemorrhage is lung specific and not due to a generalized change in vascular permeability 
(29). While IL-6 and IL-10 are reportedly increased in the bronchiolar lavage from pristane-treated 
mice, common inflammatory cytokines, such as TNF or IFN-γ, are not, suggesting that novel inflam-
matory cytokines or chemokines may be at play, driving neutrophil and inflammatory monocyte accu-
mulation and associated pathology (29).
As with many human diseases, dysregulated expression of  noncoding RNAs, including microRNA, 
has been associated with immunopathology of  SLE (31). miR-125a is one such microRNA. Its expres-
sion is reportedly decreased in SLE patients and regulates a number of  important immunoregulatory 
processes, including the expression of  inflammatory cytokines and chemokines (32). Importantly, miR-
125a is associated with a number of  inflammatory diseases, including SLE (32), rheumatoid arthritis 
(33), and Crohn’s disease (34). More recently, miR-125a has been shown to play a role in protecting 
against LPS-induced acute lung inflammation via its ability to regulate neutrophil development and 
infiltration into the lung in response to LPS (35).
Our studies demonstrate that not only are miR-125a levels decreased in SLE patient monocytes 
and peripheral blood mononuclear cells (PBMCs), but that decreased levels strongly associate with lung 
involvement. We identify IL-16, a proinflammatory cytokine known to drive airway inflammation (36–
42), as a novel and direct target of  miR-125a. Importantly IL-16 levels are increased in SLE patients 
and associate with lung involvement. In the pristane model of  IFN-driven pulmonary inflammation and 
hemorrhage, miR-125a levels are decreased in the lung as early as 3 days after pristane administration; 
this is accompanied by an increase in neutrophil recruitment and IL-16 expression, while i.n. administra-
tion of  recombinant IL-16 exacerbates these effects. In vivo delivery of  a miR-125a mimic on the other 
hand reduces IL-16 expression and protects against pristane-induced lung inflammation, with chemok-
ines such as CCL2 and CXCL10 affected. Our results reveal that IL-16 acts directly on lung epithelial 
cells to activate p38 MAPK and NF-κB and subsequent chemokine expression. Thus, alterations in miR-
125a levels in the lung result in enhanced expression of  the proinflammatory cytokine IL-16 that, in turn, 
exacerbates lung inflammation by driving chemokine expression by lung epithelial cells, suggesting that 
a novel IL-16/miR-125a axis regulates autoimmune-induced lung inflammation.
Results
miR-125a is decreased in SLE patient monocytes and targets IL-16 gene expression. In an initial effort to identi-
fy differentially expressed miRNA in monocytes isolated from SLE patients, expression of  >800 miR-
NAs in pooled samples derived from 5 SLE and 5 healthy control monocytes were investigated using the 
nCounter Human miRNA Assay (NanoString Technologies). 32 miRNAs were altered in patients with 
SLE as compared with normal controls: 14 were increased greater than 2-fold in SLE patient monocytes 
compared with controls and 18 were decreased, including miR-155, which was previously reported to be 
decreased in SLE patients (Supplemental Figure 1; supplemental material available online with this arti-
cle; https://doi.org/10.1172/jci.insight.120798DS1). Among these, miR-125a-5p (miR-125a), of  interest 
due to previous reports showing an association with SLE (32), was found to be decreased in a larger 
cohort of  monocytes derived from 15 patients with SLE and 18 healthy controls (Figure 1A). KLF13, 
a transcription factor known to regulate the chemokine RANTES is a reported target of  miR-125a (32); 
however, no significant difference in KLF13 expression was observed in monocytes from SLE patients 
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compared with healthy controls (Supplemental Figure 2A), prompting us to explore additional targets. 
Comparing 3 miRNA target prediction programs, Target scan, PicTar, and miRDB, we identified IL-16 
as a putative target of  miR-125a and determined that the 3′-UTR of  IL-16 predicted to pair with miR-
125a is evolutionarily conserved (Figure 1B). In keeping with IL-16 as a putative target, SLE monocytes 
expressed higher levels of  IL-16 compared with monocytes from healthy controls (Figure 1C), and serum 
levels of  IL-16 protein were also significantly elevated compared with controls (Figure 1D).
To establish miR-125a as regulator of  IL-16 gene expression, transfection of  monocytes from healthy 
controls with a miR-125a mimic significantly reduced IL-16 expression (Figure 1E), whereas a miR-125a 
antagomir enhanced its expression (Figure 1F). To determine if  the effects of  miR-125a on IL-16 expression 
were direct, we cloned 2 regions of  the IL-16 3′UTR into a luciferase reporter construct — one containing 
the conserved putative miR-125a–binding site (site 1) and the other containing a region that contained no 
miR-125a binding site, the unrelated fragment control (site 2). Cotransfection of  HEK293T cells with the 
two reporter constructs with either the miR-125a mimic or negative control demonstrated that transfection 
of  HEK293T cells with miR-125a mimic significantly attenuated site 1 luciferase activity but failed to 
inhibit activity of  the site 2 luciferase construct (Figure 1G), indicating that miR-125a directly targets the 3′ 
UTR of  IL-16. RNA pulldown of  biotinylated miR-125a or a negative control, which was transfected into 
HeLa cells for 24 hours, demonstrated that the IL-16 transcript was enriched in the miR-125a pulldowns, 
compared with negative control (Figure 1H). Taken together, our data demonstrate that IL-16 is to our 
knowledge both a novel and direct target of  miR-125a.
miR-125a and IL-16 levels associate with SLE lung involvement and are altered in pristane-inducible lung inflam-
mation in B6 mice. To determine the functional relevance of  enhanced IL-16 expression in SLE, we looked 
at the potential clinical relevance of  alterations in IL-16 expression in patient serum. This analysis showed 
that a higher serum IL-16 level was positively associated with autoantibodies against double-stranded DNA 
(dsDNA), a marker of  more severe disease phenotype (Supplemental Figure 2B). Interestingly, while no 
significant change in IL-16 levels was observed in SLE patients with renal (Supplemental Figure 2C) or 
CNS involvement (Supplemental Figure 2D), elevated levels of  IL-16 were observed in SLE patients with 
lung involvement (Figure 2A), while miR-125a levels were significantly decreased (Figure 2B). 16 of  42 
patients were diagnosed with lung involvement using the criteria outlined in the Methods, in keeping with 
documented levels (43).
A diagnosis of  lung involvement in lupus rarely indicates the need for a lung biopsy clinically. Thus, 
to address a possible association between IL-16 and miR-125a in lupus lung involvement, we turned to 
the pristane model of  IFN-inducible lupus. As expected pristane led to a significant influx of  neutrophil 
populations (Supplemental Figure 3A) and Ly6Chi and Ly6Cint monocytes (Supplemental Figure 3B) 
into the peritoneum as compared with that in mice treated with PBS. This increase was accompanied 
by an influx of  neutrophils and Ly6Cint monocytes (Supplemental Figure 3C) in the lungs of  mice 3, 7, 
and 14 days after pristane treatment. Importantly, no increase in CD4+ T cells was observed, whereas 
CD8+ T cell numbers were significantly increased on day 14 (Supplemental Figure 3D). Consistent with 
published reports, alveolar hemorrhage was observed 10–14 days after pristane injection, with tissue 
sections from pristane-injected mice showing more extensive infiltration of  immune cells into the lung 
and alveolar hemorrhage (Supplemental Figure 3E).
Regarding the effects of  this model on miR-125a and IL-16 levels in the lungs, we observed signifi-
cantly reduced expression of  murine miR-125a from day 7 onward after pristane administration com-
pared with that in PBS-treated mice (Figure 2C), with a corresponding increase in Il-16 expression 
observed after day 7 (Figure 2D). Intracellular flow cytometric analysis of  immune cells positive for 
IL-16 revealed that monocytes in the peritoneal cavity (Figure 2E) and CD4+ T cells in the lung (Figure 
2F) stained for IL-16 following pristane challenge. Importantly, lung expression of  neither Klf13 nor its 
target gene, Ccl5/Rantes, was altered by pristane administration, indicating that the effects of  miR-125a 
are independent of  Klf13 in this setting (Supplemental Figure 3F). In keeping with the enhanced gene 
expression, IL-16 staining was increased in lung sections from pristane-treated mice (Supplemental Fig-
ure 3G). Regarding what could potentially drive the expression of  IL-16 in pristane-induced SLE, sple-
nocytes isolated from wild-type B6 mice were treated with LPS, IFN-α, murine antinuclear antibody 
(mANA) complexes, CpG, IFN-γ, and IL-23 for 24 hours. We observed that LPS, IFN-α, and IL-23 
strongly induced expression of  IL-16, whereas responses to mANA complexes and CpG were induced 
1.5- and 2-fold, respectively, and did not reach significance (Figure 2G). Analysis of  IL-16 expression 
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in bone marrow–derived macrophages (BMDMs) from B6 or SLE-prone B6.SLE123 mice demonstrat-
ed that IFN-α could induce IL-16 expression in BMDMs from B6 mice, whereas enhanced expression 
of  IL-16 was observed basally and following stimulation with both LPS and IFN-α of  BMDMs from 
B6.SLE123 mice (Figure 2H).
In vivo delivery of  a miR-125a mimic reduces IL-16 expression and neutrophil recruitment and attenuates 
pristane-induced lung inflammation. We next investigated whether in vivo manipulation of  miR-125a levels 
could attenuate both IL-16 expression and lung inflammation by complexing 10 nmoles of  a miR-125a 
mimic with Invivofectamine 3.0 and delivering it i.p. 1 day prior to pristane injection. Enhanced miR-
125a levels were observed in the lungs of  miR-125a mimic-treated mice compared with those treated with 
negative control (Figure 3A). Analysis of  lung digests between the different treatment groups (by qPCR 
and intracellular flow cytometry) showed that treatment with the miR-125a mimic significantly blocked 
Figure 1. IL-16 a direct target for miR-125a in SLE monocytes. (A) hsa-miR-125a expression in 15 SLE patients and 18 healthy controls (CTL), as determined 
by qPCR. (B) Schematic representing conserved sequences of miR-125a–binding sites in the 3′-untranslated region (3′ UTR) of IL-16 in human, rat, and mouse 
genomes. (C) Expression of IL-16 in 15 SLE patients and 16 healthy controls, as determined by qPCR. (D) Serum IL-16 in 42 SLE patients as compared with 10 
healthy controls detected by ELISA. For A, C, and D, each point represents a single subject; horizontal lines show the mean ± SEM. **P ≤ 0.01, ***P ≤ 0.001. 
(E and F) Expression of miR-125a and IL-16 in miR-125a mimic- or anti-miR-302d–transfected monocytes, as determined by qPCR. (G) Luciferase activity in 
HEK293T cells transfected with the 3′ UTR of IL-16 containing the miR-125a–binding site (site 1) and an unrelated fragment control (site 2) and either 50 nm neg-
ative control or miR-125a mimic. (H) Bi-miR-125a pulldown was performed followed by analysis of IL-16 expression by qPCR. For E–G, values represent the mean 
± SD of 3 samples; the data shown are representative of 3 independent experiments. *P ≤ 0.05, **P ≤ 0.01, as determined by Student’s t test.
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pristane-induced IL-16 expression at the mRNA (Figure 3B) and protein level (Figure 3C), in addition 
to reducing neutrophil influx (Figure 3D). Importantly, treatment with the miR-125a mimic appeared to 
target IL-16 produced by neutrophils to a greater extent than CD4+ T cells, as determined by intracellular 
flow cytometry of  lung immune cells (Figure 3, E and F, respectively). H&E staining of  tissue sections 
from the lungs of  miR-125a mimic-treated mice revealed less pristane-mediated alveolar hemorrhage 
compared with the negative control-treated group, as shown in Supplemental Figure 4A. It should be 
noted that, although the degree of  alveolar hemorrhage observed was moderate rather than severe in the 
pristane group overall, mir-125a administration protected against lung damage in this model (Supple-
mental Figure 4B). Interestingly, miR-125a delivery did not alter recruitment of  Ly6Chi/int monocytes, 
CD4+ T cells, or B cell numbers in the lung after pristane administration (Supplemental Figure 4, C–F). 
A reduction in the expression of  2 IFN-stimulated genes (ISGs), Isg15 and Mx1, was observed, although 
changes were not found to be significant (Figure 3, G and H, respectively).
Figure 2. Altered levels of miR-125a and IL-16 associate with lung disease in SLE patients and in pristane-induced lung inflammation. (A) IL-16 serum 
levels in SLE patients with (n = 16) and without respiratory involvement (n = 24), as measured by ELISA. (B) miR-125a expression in SLE patients with (n = 
12) and without respiratory involvement (n = 19), as determined by qPCR. (C and D) Expression miR-125a (C) and Il-16 (D) was analyzed in the lungs of pris-
tane-treated B6 mice by qPCR. (E and F) Percentage of IL-16–expressing (E) Ly6Chi monocytes and (F) CD4+ T cells shown following intracellular detection of 
IL-16 by flow cytometry. For C–F, n = 10 for each group; data were analyzed using Mann Whitney U test. (G) qPCR analysis of Il-16 expression in splenocytes 
isolated from wild-type B6 mice stimulated with LPS (1,000 ng/ml), IFN-α (500 U/ml), IFN-γ (500 U/ml), murine antinuclear antibodies (ANA) (10 ng/ml), 
CpG (3 μg/ml), and IL-23 (25 ng/ml) for 3 hours. (H) Expression of Il-16 in bone marrow–derived macrophages (BMDMs) isolated from wild-type B6 or SLE-
prone B6.SLE.123 mice stimulated with LPS (100 ng/ml) and IFN-α (104 U/ml) for 6 hours. For A and B, data shown represent mean ± SD. *P ≤ 0.05, **P ≤ 
0.01 as determined by Mann Whitney U comparison. For C–G, data shown represent mean ± SD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 as determined by 1-way 
ANOVA. Values shown are from 2–3 independent experiments each with 3 replicates.
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IL-16 drives recruitment of  neutrophils into the lung following pristane administration through induction of  
CXCL10 from lung epithelial cells. Considering the direct ability of  IL-16 to induce lung inflammation, we 
assessed immune cell recruitment to the peritoneal cavity and lungs of  pristane-treated IL-16–deficient 
mice. Our results showed that neutrophil recruitment alone was altered in the IL-16–/– mice in either 
compartment (Figure 4A). We next assessed the direct effect of  recombinant IL-16 delivery on neutro-
phil recruitment. In the IL-16–deficient mice, intranasal (i.n.) delivery of  IL-16 (1 μg/mouse, 24 hours 
after administration of  pristane and thereafter every 4 days) resulted in rescue of  neutrophil recruitment 
in response to pristane (Figure 4A). In wild-type B6 mice, i.n. IL-16 alone had no effect in altering 
neutrophil recruitment (Figure 4B). However, in combination with pristane it was found to exacerbate 
recruitment of  neutrophils (Figure 4B). With or without pristane, i.n. IL-16 failed to elicit changes 
in recruitment of  inflammatory Ly6Chi monocytes or CD4+ T cells to the lung (Supplemental Figure 
5, A and B, respectively). While i.n. IL-16 alone appeared to marginally (although not significantly) 
enhance expression of  the ISGs Isg15 and Mx1 in the lung, no further enhancement of  expression of  
either gene was observed following pristane injection (Supplemental Figure 5, C and D, respectively). 
Additionally, i.n. IL-16 further drove increased IL-16 production, which could be detected in the bron-
choalveolar lavage fluid and systemically (Supplemental Figure 5, E and F, respectively). In assessing 
gene expression changes by qPCR in lung digests from pristane-treated mice, we observed a number of  
key chemokines that were elevated, including CXCL10, which was recently recognized as a key player 
in neutrophil-mediated lung inflammation (Supplemental Figure 5G) (28, 44). We therefore assessed 
the role of  IL-16 in mediating CXCL10 levels and found that, while pristane alone could drive Cxcl10 
expression in the lung, i.n. IL-16 significantly exacerbates pristane-driven Cxcl10 induction in the lungs 
Figure 3. In vivo delivery of miR-125a mimic reduces neutrophil recruitment and IL-16 expression and attenuates pristane-induced lung pathology. 
(A–F) Mice received a single i.p. injection (10 nmol) of a miR-125a mimic or negative control (n = 10 for each treatment group) for 1 day before the i.p. 
injection of 500 ml pristane followed by sacrifice at 10 days for analysis. (A) Expression of miR-125a is altered in the lungs following administration 
of miR-125a compared with negative control. (B) Il-16 levels in the different treatment groups were analyzed in the lungs by qPCR. (C and D) Flow 
cytometry of cell populations in lung digests of the different treatment groups was performed. Percentage of IL-16–expressing cells (C) and neutro-
phils (D) in the lung. (E and F) Percentage of IL-16–expressing (E) Ly6G+ neutrophils and (F) CD4+ T cells following intracellular detection of IL-16 by 
flow cytometry. (G and H) Expression of (G) Isg15 and (H) Mx1 in the lungs of the different treatment groups analyzed by qPCR. For A, B, E, and F, 
data shown represent mean ± SD. *P ≤ 0.05, **P ≤ 0.01 as determined by unpaired t test. For C, D, G, and H, data shown represent mean ± SEM. *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001 as determined by 1-way ANOVA.
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of  pristane-treated B6 mice (Figure 4C). Meanwhile in vivo delivery of  a miR-125a mimic resulted in 
reduced chemokine expression, including Cxcl10 expression in the lungs in pristane-treated mice (Figure 
4, D and E), further supporting a role for mir-125a as a negative regulator pristane-induced lung inflam-
mation via its ability to target IL-16.
To assess whether IL-16 directly regulated chemokine expression in the lung, we analyzed Cxcl10 
mRNA expression in murine precision cut lung slices (PCLSs) in response to IL-16 stimulation. As 
shown in Figure 5A, ex vivo stimulation of  PCLSs with IL-16 induced an increase in Cxcl10 expression, 
whereas transfection of  PCLS with miR-125a resulted in a reduction in both Il-16 and Cxcl10 expres-
sion (Figure 5B). Immunofluorescent detection of  Cxcl10 in PCLSs treated with IL-16 demonstrated 
that Cxcl10 protein levels were indeed elevated and that Cxcl10 appeared to colocalize with E-cad-
herin, a marker for epithelial cells (Figure 5C). As IL-16 has previously been shown to directly act on 
lung epithelial cells and induce apoptosis (36), we assessed the effects of  IL-16 on the human bronchial 
epithelial cell line 16HBE14o-. IL-16 stimulation enhanced activity of  p38 MAPK and NF-κB (32), as 
determined by Western blotting for phospho-p38 and phospho-p65 (Figure 5D), in addition to driving 
CXCL10 gene expression (Figure 5E). Inhibition of  p38 MAPK, NF-κB, or PKC pathways (previously 
reported to be activated by IL-16; ref. 45, 46) in either 16HBE14o- cells (Figure 5E) or murine PCLSs 
(Figure 5F) with SB203580 (p38 inhibitor), BMS-345541 (NF-κB inhibitor), and bisindolylmaleimide I 
(PKC inhibitor) blocked the ability of  IL-16 to drive CXCL10 expression, indicating that IL-16 directly 
acts on lung epithelial cells to drive chemokine expression. Our studies, therefore, identify IL-16 as a 
target for mir-125a and demonstrate a pathogenic role for IL-16 in driving autoimmune lung inflam-
mation via its ability to directly induce inflammation via direct effects on lung epithelial cells.
Figure 4. miR-125a/IL-16 axis drives pristane-induced cellular recruitment of neutrophils to the lung. (A) Flow cytometry analysis of neutrophils 
in the peritoneal lavage and lung digests of B6 or IL-16–/– mice following treatment with pristane or PBS (n = 8 per group). (B) rmIL-16 (1 μg) was 
administered to B6 mice i.n. 1 day after pristane challenge followed by i.n. IL-16 every 4 days thereafter (n = 4–7 for each group, 2 independent 
experiments). Flow cytometry analysis of the percentage of neutrophils in the lung digests of the different treatment groups at day 14. (C) Cxcl10 
expression in the lung in the different treatment groups, as measured by qPCR. (D) Mice received a single i.p. injection (10 nmol) of miR-125a mimic 
or negative control mimic (n = 10) for 1 day before pristane challenge followed by sacrifice at 10 days for analysis. miR-125a inhibited pristane-in-
duced chemokine expression, as measured by qPCR. (E) Cxcl10 expression in the lungs in the different treatment groups, as measured by qPCR. 
Data were analyzed using the Mann Whitney U test; mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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Discussion
Acute autoimmune lung manifestations include alveolar hemorrhage — a devastating and potentially 
fatal complication associated with SLE as well as other autoimmune conditions. The immune events that 
mediate the pathology underlying this condition are relatively unknown, and very little information exits 
regarding what may influence predisposition to either lung involvement or acute autoimmune lung inju-
ry in SLE. In this study, we have identified a mechanism regulating lung inflammation in the context of  
SLE — decreased expression of  the microRNA miR-125a associates with lung involvement via its ability 
to regulate the proinflammatory cytokine IL-16 directly. Mechanistically, we show that enhanced IL-16 
expression in the murine lung drives enhanced recruitment of  neutrophils to the lung via a direct ability to 
activate lung epithelial cells.
Type I IFNs are central to inflammatory responses in the lung, not only activating lung epithelial cells 
and resident immune cells, but also inducing the expression of  cytokines and chemokines (CCL2/MCP-1, 
CCL3/MIP-1α, and CXCL10/IP-10, for example) and hence influencing inflammation via recruitment 
and activation of  neutrophils, monocytes, and T cells in the lung (18–27). Our results show that IFN-α can 
induce IL-16 expression in murine splenocytes and BMDMs directly and that in the pristane model of  SLE, 
Figure 5. IL-16 acts directly on lung epithelial cells. (A and B) Precision cut lung slices (PCLS) were prepared from low-melting agarose-perfused wild-type B6 
mouse lungs. Slices were (A) stimulated with IL-16 (100 ng/ml) for 6 hours or (B) transfected with a miR-125a mimic or negative control for 48 hours. Cxcl10 
expression was analyzed by qPCR. A representative graph is shown; n = 3. Mean ± SD. Data were analyzed using unpaired t test. (C) PCLS were stimulated with 
IL-16 (50 ng/ml) for 3 hours and immunostained for Cxcl10 (green), E-cadherin (red), and DAPI (blue). Scale bar: 200 μm. Original magnification, ×20; ×2 (insets). 
(D) 16HBE14o- cells were treated with IL-16 for different time points, as indicated. Expression of total p38, phospho-p38, total NF-κB p65, and phospho-NF-κB 
p65 was analyzed by immunoblotting. Activation of p38 and NF-κB was determined by the ratio of phosphorylated bands to total bands, respectively. Error bars 
represent SEM of 3 independently repeated experiments (n = 3). (E and F) 16HBE14o- cells (E) and PCLS (F) were pretreated with inhibitors as indicated for 1 hour 
and stimulated with IL-16 for 6 hours followed by qPCR for CXCL10. For D–F, data were analyzed by 1-way ANOVA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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an IFN-α–driven model, IL-16 expression is induced both in the lung and systemically. IL-16 is a multi-
functional inflammatory cytokine that acts on T cells, monocytes, and eosinophils, driving migration and 
regulating activity (36–42). Initially studied in the context of  asthma, IL-16 was shown to recruit CCR5-ex-
pressing Th1 cells to sites of  allergic inflammation and drive T regulatory cell expansion, acting to protect 
in models of  Th2-driven asthma (47–50). However, in an inflammatory setting, IL-16 has been found to 
exacerbate Staphylococcus aureus infections in the lung; although, how it mediates its effects in this setting 
has not yet been fully elucidated (51). In models of  chronic lung inflammation, such as bleomycin-induced 
lung injury, IL-16 is upregulated but does not appear to play a role in pathology in this model (52).
As to what regulates IL-16 expression in this model, we have shown that miR-125 directly regulates 
IL-16 expression in monocytes and that its expression is decreased in monocytes from SLE patients, in 
keeping with previous reports showing that miR-125a levels are decreased in PBMCs of  SLE patients (32). 
In keeping with this observation, we report decreased miR-125a in SLE monocytes and identify the proin-
flammatory cytokine IL-16 as a possible novel and direct target of  miR-125a, whose expression is elevated 
in SLE monocytes. Both gain- and loss-of-function studies demonstrate that transfecting monocytes with 
miR-125a mimic or antagomir has reciprocal effects on IL-16 expression, while analysis of  the ability of  
biotinylated miR-125a to bind the 3′ UTR of  IL-16 confirms IL-16 as a direct target. Increased circulating 
IL-16 levels have been reported previously in SLE patients, with increased levels correlating positively with 
SLE disease activity scores (53). In keeping with, this we demonstrate an association between circulating 
IL-16 levels and dsDNA positivity status in our SLE cohort, a marker of  more severe disease (54). More 
importantly, we observe a strong association between alterations in miR-125a and IL-16 levels in SLE 
patients who experienced respiratory involvement (namely pleuritis or alveolar hemorrhage) compared 
with those with other organ involvement, indicating a possible involvement of  miR-125a-IL-16 in lung 
inflammation in the context of  SLE. It is possible that the decreases in miR-125a and increases in IL-16 
that we observe more generally across our SLE cohort reflect a phenomenon that has widely been reported 
— that autoimmune lung involvement, be it alveolitis, interstitial lung disease, or the observance of  ground 
glass opacities, is more widely present but remains undetected in the absence of  conducting pulmonary 
function tests (PFTs) or high-resolution CT (HRCT) scans. Such testing in rheumatoid arthritis patients, 
for example, with early-stage disease, has revealed a much higher level of  lung involvement than previously 
thought, with 35% percent showing ground glass opacities on HRCT (55). In keeping with these reports, 
a number of  studies have shown that asymptomatic SLE patients have a much higher involvement of  lung 
inflammation in SLE on PFT or HRCT scan than previously stated (56, 57). Therefore, the possibility exists 
that unconfirmed subclinical lung involvement accounts for our observations.
Using the pristane model of  acute autoimmune lung disease, we show that reduced miR-125a expres-
sion in the lungs of  pristane-treated mice correlates with increased IL-16 expression and that CD4+ T cells 
and monocytes are the most likely source of  IL-16 in this setting. However, while neutrophil numbers 
are increased in the pristane lung, surprisingly alterations in CD4+ T cells are not observed. A number of  
publications have shown that IL-16 can induce chemotaxis of  other immune cells, such as monocytes and 
eosinophils, in addition to CD4 T cells (40, 41). However, in this model, it appears that IL-16 regulates neu-
trophil rather than CD4+ T cell recruitment, with i.n. administration of  IL-16 enhancing pristane-induced 
neutrophil recruitment, but with no effect on CD4+ T cell recruitment. In contrast, administration of  a 
miR-125a mimic completely reversed IL-16 expression in response to pristane and, more importantly, pris-
tane-induced neutrophil accumulation. Importantly, these observed increases in neutrophil infiltration in 
the lung were associated with increased expression of  chemokines, such as CXCL10, a chemokine known 
to regulate CD4+ T cell recruitment that has been shown to play an important role in lung pathology via its 
ability to regulate neutrophil recruitment (28).
In models of  acute lung injury, the accumulation of  neutrophils in the lung is CXCL10 dependent, driv-
en in part by increased expression of  CXCR3 on infiltrating neutrophils (28). Although we were not able 
to observe changes in CXCR3 expression in our model, we found that IL-16 acts directly on lung epithelial 
cells to enhance expression of  CXCL10. The ability of  IL-16 to directly induce chemokine expression from 
lung epithelial cells is supported by previous observations showing, first, that IL-16 directly acts on alveolar 
basal lung epithelial cells (36) and, second, that lung epithelial cells produce CXCL10 both in vitro and in 
vivo in response to human rhinovirus type 16 infection in an NF-κB–dependent manner (58). Our results 
show that IL-16 acts on bronchial epithelial cells to activate p38 MAPK, PKC, and NF-κB–dependent 
pathways (45, 46) to enhance expression of  CXCL10. Our data therefore indicate that IL-16 can directly 
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act on lung epithelial cells to induce upregulation of  neutrophil-attracting chemokines, such as CXCL10. 
Importantly, in vivo delivery of  miR-125a suppressed both IL-16 and CXCL10 expression and reduced 
neutrophil accumulation in the lungs of  pristane-treated mice, supporting a key role for the miR-125/IL-16 
axis in mediating neutrophil accumulation in the lung in the context of  autoimmune lung inflammation. 
How neutrophils contribute to autoimmune lung pathology in this model remains to be elucidated. Recent 
work has demonstrated the role of  low-density neutrophils and NETosis in SLE organ pathogenesis via 
the ability of  low-density neutrophils to release potential autoantigens such as self-DNA and nuclear-as-
sociated material, specifically in the context of  cardiovascular disease (8–10). Histologically, autoimmune 
diffuse alveolar hemorrhage of  the lung is accompanied by a massive neutrophil influx that is thought to 
contribute to pathology through the release of  reactive oxygen species and antimicrobial peptides, such as 
defensins (7). However, a number of  studies have suggested that there is no role for neutrophil NETosis in 
the pathogenesis of  lupus using MRL.Faslpr mice crossed to either Pad4- or Nox2-deficient animals. Loss 
of  Nox2 and NADPH oxidase activity resulted in an exacerbation of  kidney disease (59), whereas PAD4 
deficiency had no effect on glomerulonephritis in the MRL.Faslpr model (60) but exacerbated both kidney 
disease and ANA production in pristane-induced lupus (61). Thus, further work is required to elucidate the 
role of  neutrophils in end-organ disease and their contribution to autoimmune lung specifically.
Taken together, our results demonstrate an important association between miR-125a and its target 
IL-16 in SLE-associated lung involvement and reveal a role for IL-16 in acting directly on lung epithelial 
cells to drive chemokine expression and, hence, contribute to neutrophil accumulation. Our results reveal 
that modulation of  IL-16 expression, either by direct i.n. administration or via targeting it with miR-125a 
mimics, alters neutrophil recruitment and, therefore, lung inflammation in the context of  autoimmune 
lung inflammation. Our data strongly support a role for IL-16–induced chemokine expression in driving 
of  neutrophil influx and potentially pathology and suggest the miR-125a/IL-16 axis as a target for auto-
immune lung injury.
Methods
Patients and controls and handling of  samples. All SLE patients were recruited from Beaumont Hospital; St. 
James’s Hospital, Dublin, Ireland; St. Vincent’s University Hospital; and Cedars-Sinai Medical Center, as 
per ACR diagnostic criteria (62). Clinical data were determined for each patient at the time of  the blood 
draw (Table 1). Lung involvement was defined in this study as evidence of  pleuritic chest pain, with evi-
dence of  a pleural rub, effusion, or thickening (SLEDAI-2K) (63) or pleurisy, pleural effusion with dyspnea, 
pulmonary hemorrhage, interstitial alveolitis/pneumonitis, and shrinking lung syndrome (BILAG 2004 
index) (64). Age- and sex-matched healthy donors who had no history of  autoimmune diseases or treat-
ment with immunosuppressive agents were included.
Isolation of  CD14+ monocyte cells. PBMCs were separated from the whole blood of  patients with SLE and 
healthy control subjects by density-gradient centrifugation with Ficoll-Paque Plus (GE Healthcare). CD14+ 
monocytes were purified from fresh PBMCs by positive selection using magnetic CD14+ beads (Miltenyi 
Biotec) according to the manufacturer’s protocol. Purified monocytes were cultured in phenol red–free 
RPMI 1640 medium supplemented with 10% charcoal–stripped fetal calf  serum and 100 μg/ml penicillin/
streptomycin.
Real-time PCR analysis. RNA was extracted from cell cultures using TRIzol reagent (MilliporeSigma) 
according to the manufacturer’s protocol. Expression of  >800 miRNAs was assessed by NanoString Tech-
nologies using nCounter miRNA Expression Assays. To validate the results, miR-125a expression was ana-
lyzed using the miScript primer assay (Qiagen, MS00003423) and miScript SYBR Green PCR kit (Qiagen), 
with normalization to the U6 small nuclear RNA. RNA was reverse transcribed using the iScript Reverse 
Transcription Supermix Kit (Bio-Rad) according to the manufacturer’s recommendations. Real-time qPCR 
investigating human IL-16, KLF13, and CXCL10 gene expression was performed using appropriate primers 
(Table 2) with the SYBR Green Taq ReadyMix (MilliporeSigma) according to the manufacturer’s recom-
mendations. Data were analyzed using an ABI Prism 7900 system (Applied Biosystems) and were normal-
ized to an 18S rRNA reference. Murine Il-16, Klf13, Mx1, Isg15, Ccl5, and Cxcl10 gene expression was per-
formed using appropriate primers (Table 2) with the PerfecTa SYBR Green PCR Kit (Quanta, 95072-012) 
as per the manufacturer’s recommendations. Data were analyzed in triplicate using an ABI Prism 7900HT 
system (Applied Biosystems) and were normalized to an L32 RNA reference. Real-time PCR data were 
analyzed using the 2-ddCt method (65).
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Western blotting. To prepare whole-cell lysates, cells were lysed in SDS buffer 
(250 mM Tris-HCl, pH 6.8, 10% SDS, 0.5% bromophenol blue, 50% glycerol, 
50 nM DTT) and boiled at 95°C for 10 minutes. Equal quantities of  whole-cell 
lysates were resolved by electrophoresis on a denaturing SDS–polyacrylamide 
gel according to the method of  Laemmli (66) and transferred to a nitrocellu-
lose membrane for immunoblotting. The antibodies used for immunoblotting 
included anti–α-actinin (Cell Signaling Technology), anti–phosphorylated p38 
MAPK (Cell Signaling Technology), anti-p38 MAPK (Cell Signaling Technol-
ogy), anti-phosphorylated p65 (Santa Cruz Biotechnology), and anti-p65 (San-
ta Cruz Technology). Following immunoblotting, the membrane was devel-
oped using enhanced chemiluminescent HRP substrate (Millipore). Optical 
densitometry was performed using Image Studio Lite (LI-COR Bioscience).
Mimic and inhibitor transfection. MicroRNA-125a oligonucleotides were 
obtained from Dharmacon. Negative controls were based on the sequences 
of  miRNA in Caenorhabditis elegans (cel-miR-67). Reverse transfection of  
human primary monocytes was performed using Metafectene SI transfec-
tion reagent (Biontex Laboratories Gmbh) as recommended by the man-
ufacturer’s protocol. Evaluation of  the experiment was carried out 48–72 
hours after transfection.
Luciferase reporter assay. The putative miR-125a target sequence in the 3′ 
UTR of human IL-16 (site 1) and an unrelated fragment control region of  the 3′ 
UTR of human IL-16 (site 2) was cloned into the psiCHECK-2 vector (Prome-
ga) downstream of the Renilla luciferase reporter gene with the following prim-
ers: site 1, forward, 5′-GAGAGACTCGAGCTGAAGCCAAAGCCAATA-3′ 
and reverse, 5′-GAGAGAGCGGCCGCTGTCATATGAAATTCTAATA-3′; 
site 2, forward, 5′-GAGAGACTCGAGGCTTAATGATAATATTGTGG-3′ 
and reverse, 5′-GAGAGAGCGGCCGCTATGAGTGAATGATCTCACG-3′.
All constructs were sequenced and were prepared with the use of  an End-
oFree Plasmid Maxi kit (Qiagen). 293T cells were seeded at 1 × 105 cells/
well in a 96-well plate 1 day before transfection and then transfected with a 
mixture of  50 ng IL-16–UTR site 1 or site 2 luciferase reporter vector and 50 
nM of  either a negative control or miR-125a mimic. The cells were harvested 
24 hours later, and luciferase activity was assessed using a Dual Luciferase 
Reporter Assay System (Promega). Firefly luciferase was used to normalize 
the Renilla luciferase. All experiments were carried out in triplicate.
Biotin miR-125a pulldown. HeLa cells (1 × 106 cells/well) were transfected 
in triplicate with Bi-miR-125a or Bi-negative control miRNA (Dharmacon) as above for 24 hours. Briefly, 
cells were lysed in 1 ml lysis buffer (20 mM Tris [pH 7.5], 100 mM KCL, 5 mM MgCl2, 0.3% NP-40, 50 
U RNase OUT [Invitrogen], and complete mini-protease inhibitor cocktail [Roche]) and incubated on ice 
for 5 minutes. Streptavidin-coated magnetic beads (Invitrogen) were blocked for 2 hours at 4°C in lysis 
buffer with 1 mg/ml yeast tRNA and 1 mg/ml BSA (Ambion), followed by washing with lysis buffer. 
Cytoplasmic lysate was added to beads and incubated for 4 hours at 4°C before washing 5 times with 1 ml 
lysis buffer. RNA bound to the beads was isolated using Trizol. IL-16 mRNA levels in the Bi-miR-125a or 
Bi-negative control pulldown were quantified by qPCR with normalization to the housekeeping gene GAP-
DH. An enrichment ratio of  pulldown RNA to input levels was calculated for IL-16.
Mice. B6 mice were purchased from The Jackson Laboratory. Mice were propagated and maintained 
in the animal facility at the Department of  Comparative Medicine (Davis Building) of  Cedars-Sinai Med-
ical Center. IL-16–/– mice were generated by Sue Kim (University of  Massachusetts Medical School) and 
HK (67) and supplied by HB. Animals were between 6 and 12 weeks old at the time of  experimentation. 
Lung cellular infiltration was induced by i.p. administration of  0.5 ml pristane (MilliporeSigma). Lung tis-
sues were collected for RNA extraction and embedded in paraffin for sectioning. The miR-125a and neg-
ative control mimics were purchased from Dharmacon. Invivofectamine 3.0 in vivo transfection reagent 
was purchased from Thermo Fisher Scientific. The transfection protocol was based on the manufacturer’s 
instructions. Briefly, 100 μl of  1.2 mg/ml miRNA solution was prepared by adding 50 μl complexation 
Table 1. Demographic characteristics of SLE patients 
involved in this study (n = 42)
Sex 
Female 37
Male 5
Age, mean (± SD) 38.9 (± 12.9)
Disease duration, mean (± SD) 6.9 (± 5.9
ACR classification criteria
ANA 42 (100 %)
Malar rash 30 (71%)
Discoid rash 2 (7%)
Photosensitivity 22 (52%)
Oral ulcers 14 (33%)
Arthritis 23 (55%)
Serositis 18 (45%)
Renal 14 (33%)
CNS disease 8 (19%)
Hematologic 31 (73%)
Immunologic disorder 29 (69%)
SLEDAI (median ± IQR) 2 (0–4)
SLICC damage index (median ± IQR) 0 (0–1)
Lung involvement 16/42
Autoantibody profile
Anti-dsDNA 29 (69%)
Anti-Ro  16 (38%)
Anti-La 7 (16%)
Anti-RNP 6 (14%)
Anti-Sm 4 (10%)
Current immunosuppression
Prednisolone 20 (47%)
Hydroxychloroquine 33 (78%)
Azathioprine 13 (30%)
Mycophenolate mofetil 4 (10%)
Cyclophosphamide 1 (2%)
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buffer to 50 μl of  2.4 mg/ml solution of  miR-125a or negative control. This solution was immediately 
added to 100 μl Invivofectamine 3.0 transfection reagent, which was then mixed well to ensure complete 
complexation. The mixture was incubated at 50°C for 30 minutes. The complex was then diluted 6-fold 
with sterile PBS, pH 7.4, and mixed well. For each injection, we used 200 μl of  working solution (10 nm 
of  the miR-125a mimic/negative control mimic).
To assess direct effects of  IL-16 on the lung, IL-16 was i.n. delivered 1 day after pristane challenge and 
then followed by i.n. delivery every 4 days until day 14. Mice were sacrificed for tissue and blood 14 days 
after injection unless otherwise indicated. Recombinant IL-16 was purchased from Cell Guidance Systems 
(catalog GFM49) and had ≤1.00 EU/μg endotoxin, as measured by LAL.
Immunohistochemistry. The mice were sacrificed, and lungs were perfused with ice-cold PBS prior to 
removal. Lungs were fixed for 24 hours in 10% neutral buffered formalin then stored in 70% ethanol until 
they were embedded in paraffin and sectioned at 5 μm. The slices were deparaffinized in xylene and rehy-
drated to graded changes of  ethanol. Antigen retrieval was performed using a pressure cooker by heating 
the sections for 45 minutes at 95°C in sodium citrate buffer, pH 6.0. IL-16 staining was performed using 
the Anti-Rabbit HRP-DAPI Cell & Tissue Staining kit as per the manufacturer’s protocol (R&D Systems, 
CTS005). Briefly, endogenous peroxidase was exhausted with peroxidase blocking reagent for 5 minutes 
followed by incubation with rabbit serum-blocking reagent for 15 minutes to minimize nonspecific stain-
ing. Sections were then incubated with avidin-blocking reagent for 15 minutes followed by biotin blocking 
reagent for a further 15 minutes. The sections were incubated overnight at 4°C with a rabbit primary anti-
body against IL-16 (dilution 1:200; Santa Cruz, sc-7902) followed by HRP-conjugated secondary antibody 
for 30 minutes. The sections were then incubated with HSS-HRP followed by several washes of  PBS. The 
immunohistochemical reaction was visualized by incubation with 3,3′-diaminobenzidine tetrahydrochlo-
ride chromagen and sections were counterstained with hematoxylin. Images were captured using Aperio 
ScanScope AT Turbo.
Flow cytometry. Single-cell suspensions from lungs and peritoneal lavage were isolated from wild-
type naive and pristane-injected B6 mice. Briefly, 106 cells were suspended in FACS buffer contain-
ing 1× PBS (pH 7.2), 2% fetal bovine serum (Omega Scientific), and 0.1% sodium azide. Cells were 
stained in the relevant fluorochrome-labeled mAbs, and 10,000 events were acquired on a BD Bio-
sciences LSRII. For IL-16 intracellular staining, cell fixation and permeabilization using Cytofix/
Cytoperm buffer (BD Biosciences) were performed before antibody staining. Data analysis was per-
formed by using FlowJo V10 (Tree Star). The following monoclonal antibodies (Biolegend) were used: 
CD11b-APC, clone M1/70; Ly6G-FITC, clone 1A8; Ly6C-PerCP, clone HK1.4; CD3-APC, clone 
17A2; CD4-FITC, clone RM4-5; CD8-PE, clone 53-6.7; CD19-Pacific Blue, clone 6D5; and IL-16–PE, 
clone 14.1. Fluorochrome- and isotype-matching mAbs were used as negative controls.
PCLS preparation and culture. Wild-type B6 mice were sacrificed by isoflurane inhalation, and lungs 
were perfused with 15 ml PBS at room temperature through the right ventricle. The trachea was cannulated 
with a 20-gauge catheter (20 G × 1.00 in. BD Insyte Autoguard), and then lung lobes were inflated with 3% 
(w/v) 45°C prewarmed low-melting agarose (Promega). The inflated lung lobes were immediately removed 
and cooled on ice for 15 minutes. After lobes solidified, the left lobe was separated and sectioned into 
Table 2. Human and murine primer sequences used in qPCR
Gene Forward primer 5′–3′ Reverse primer 5′–3′
Human IL-16 GCCGAAGACCCTTGGGTTAG GCTGGCATTGGGCTGTAGA
Human KLF13 CGGCCTCAGACAAAGGGTC TTCCCGTAAACTTTCTCGCAG
Human CXCL10 GGTGGTGGTCCCCAGTAATG ACCACGTCCACAACCTTGTCT
Murine IL-16 AAGAGCCGGAAATCCACGAAA GTGCGAGGTCTGGGATATTGC
Murine KLF13 CCTCAGACAAAGGGGTCGG GTAGTGGCACTTGTGCTTCC
Murine CXCL10 CCAGTAGTGAGAAAGGGTCG AGGGCTTGGGGCAAATTGTT
Murine Ccl5 GTGCCCACGTCAAGGAGTATTT AAGCGATGACAGGGAAGCGTAT
Murine ISG15 GGTGTCCGTGACTAACTCCAT CTGTACCACTAGCATCACTGTG
Murine MX1 GATCCGACTTCACTTCCAGATGG CATCTCAGTGGTAGTCAACCC
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200-μm-thick slices using a vibratome (Leica VT 1200S, Leica Microsystems). Tissue slices were then cul-
tured in DMEM supplemented with 10% FCS, 100 μg/ml penicillin/streptomycin, and glutamine. Inhibi-
tors and stimulants were applied immediately after sectioning.
Macrophage culture. Isolation and activation of  BMDMs were performed as previously described (68).
Cell culture. 16HBE14o- bronchial epithelial cells (ATCC) were seeded in 6-well plates at a density 
of  5 × 105 cells/well in MEM with Earle’s salts, supplemented with 10% FBS and incubated at 37°C in 
5% CO2 until confluence (2–3 d). Cells were stimulated with recombinant human IL-16 (Origene, catalog 
TP720036; endotoxin levels <1.00 EU/μg, as measured by LAL) for the indicated time points prior to lysis 
and analysis of  gene expression or protein phosphorylation.
Statistics. Data were analyzed using Prism 4 software, version 4.03 (GraphPad Software). Statis-
tical analysis was performed with the 2-tailed Student’s t test or Mann-Whitney U test when the data 
were not normally distributed. Multiple comparisons between groups were performed using 1-way 
ANOVA, followed by post hoc analysis using Tukey’s comparison. Statistical significance was defined 
as a P < 0.05.
Study approval. All SLE patients were recruited from Beaumont Hospital, St. James’s Hospital, and 
St. Vincent’s University Hospital. All participants provided informed written consent, and the study 
received prior approval from the institutional ethics review boards at Beaumont Hospital, St. James’s 
Hospital, and St. Vincent’s University Hospital. The use of  human PBMCs and monocytes from 
patients and controls was reviewed and approved by the ethics review board at the Royal College of  
Surgeons in Ireland and the IRB of  Cedars-Sinai Medical Center.
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